400 related articles for article (PubMed ID: 21517928)
1. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
3. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
[TBL] [Abstract][Full Text] [Related]
5. Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4.
Pollok KE; Kim SH; Kwon BS
Eur J Immunol; 1995 Feb; 25(2):488-94. PubMed ID: 7875212
[TBL] [Abstract][Full Text] [Related]
6. Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.
Vinay DS; Kwon BS
Cell Immunol; 1999 Feb; 192(1):63-71. PubMed ID: 10066348
[TBL] [Abstract][Full Text] [Related]
7. Optimization of lentiviral vector transduction into peripheral blood mononuclear cells in combination with the fibronectin fragment CH-296 stimulation.
Chono H; Goto Y; Yamakawa S; Tanaka S; Tosaka Y; Nukaya I; Mineno J
J Biochem; 2011 Mar; 149(3):285-92. PubMed ID: 21106541
[TBL] [Abstract][Full Text] [Related]
8. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
[TBL] [Abstract][Full Text] [Related]
9. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratio.
Mercier-Letondal P; Montcuquet N; Sauce D; Certoux JM; Jeanningros S; Ferrand C; Bonyhadi M; Tiberghien P; Robinet E
Cytotherapy; 2008; 10(3):275-88. PubMed ID: 18418773
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 can replace CD28-dependent T-cell costimulation during nonspecific cytotoxic T lymphocyte induction by anti-CD3 antibody.
Makrigiannis AP; Musgrave BL; Haeryfar SM; Hoskin DW
J Leukoc Biol; 2001 Jan; 69(1):113-22. PubMed ID: 11200055
[TBL] [Abstract][Full Text] [Related]
12. Tetanus toxoid provides efficient T-cell help for the induction of HA-1(H) cytotoxic T cells.
Eiz-Vesper B; Horn PA; Daubert C; Khattab B; Blasczyk R
Transfusion; 2006 Jul; 46(7):1210-20. PubMed ID: 16836569
[TBL] [Abstract][Full Text] [Related]
13. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression.
Wehler TC; Karg M; Distler E; Konur A; Nonn M; Meyer RG; Huber C; Hartwig UF; Herr W
J Immunol Methods; 2008 Nov; 339(1):23-37. PubMed ID: 18760281
[TBL] [Abstract][Full Text] [Related]
14. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
15. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
[TBL] [Abstract][Full Text] [Related]
16. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
17. Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy.
Blum S; Milesi R; Tratkiewicz J; Olive D; Gallati H; Cerottini JC; von Fliedner V
Ther Immunol; 1994 Jun; 1(3):143-52. PubMed ID: 7584490
[TBL] [Abstract][Full Text] [Related]
18. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.
Oelke M; Moehrle U; Chen JL; Behringer D; Cerundolo V; Lindemann A; Mackensen A
Clin Cancer Res; 2000 May; 6(5):1997-2005. PubMed ID: 10815925
[TBL] [Abstract][Full Text] [Related]
19. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
Li Q; Furman SA; Bradford CR; Chang AE
Clin Cancer Res; 1999 Feb; 5(2):461-9. PubMed ID: 10037198
[TBL] [Abstract][Full Text] [Related]
20. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]